Vapotherm (NYSE:VAPO) announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.03, Morningstar.com reports. The company had revenue of $12.30 million for the quarter, compared to analysts’ expectations of $11.90 million.
Shares of NYSE:VAPO opened at $17.48 on Friday. The company has a current ratio of 6.35, a quick ratio of 5.34 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $298.81 million and a PE ratio of -1.26. Vapotherm has a 1 year low of $14.70 and a 1 year high of $22.29.
VAPO has been the subject of several recent research reports. Zacks Investment Research upgraded Vapotherm from a “sell” rating to a “hold” rating in a research report on Saturday, May 11th. Canaccord Genuity boosted their price objective on Vapotherm from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, March 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.50.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Rockland Register and is owned by of Rockland Register. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://rocklandregister.com/2019/05/31/vapotherm-vapo-announces-quarterly-earnings-results.html.
Vapotherm Company Profile
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Featured Article: Investing in Blue-Chip Stocks
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.